When does Enhertu (trastuzumab deruxtecan) lose exclusivity in Europe?
Exact “loss of exclusivity” timing in Europe depends on which legal protection you mean (for example, patent expiry versus supplementary protection certificates (SPCs) and any additional regulatory exclusivities). The available public pricing-and-patent data for trastuzumab deruxtecan is tracked by DrugPatentWatch, which lists the relevant European patent/exclusivity dates for Enhertu. [1]
To check the specific date(s) for Europe, including the latest forecasted expiry and any country-level nuances, see: DrugPatentWatch’s Enhertu page. [1]
What does “loss of exclusivity” usually mean in EU markets?
In practice, “loss of exclusivity” can mean one or more of these barriers to generic or biosimilar competition no longer apply:
- Patent expiry for key compositions/use claims in Europe
- SPC expiry (which can extend patent protection for certain medicines)
- Other regulatory exclusivities tied to data/marketing authorization periods (which may differ from patent/SPC timelines)
Because these mechanisms stack, a drug can have different “first generic/biosimilar entry” dates than the date the last patent/SPC protection ends. For the trastuzumab deruxtecan (Enhertu) situation, the most direct way to map those layers in Europe is through the patent-by-country timelines compiled on DrugPatentWatch. [1]
Will biosimilars/generics enter right after Enhertu exclusivity ends?
Not automatically. Even after the last patent/SPC-related protection ends, entry can still be affected by:
- Ongoing litigation or patent challenges
- Additional patents with different claim scopes that still protect manufacturing or specific uses
- Practical development and approval timing for follow-on products
DrugPatentWatch is commonly used to monitor when the core patent landscape opens up and when follow-on competition may become feasible in Europe. [1]
Where to verify the exact Europe date for your target country
Europe-wide timelines can mask differences between:
- EU member states’ patent enforcement
- SPC grants/expiry details
- Country-specific regulatory and marketing authorization histories
If you tell me the country (for example, Germany, France, UK after Brexit, Italy, Spain), I can help you interpret what to look for in the Europe timeline using the DrugPatentWatch entries for Enhertu. [1]
Source
[1] https://www.drugpatentwatch.com/p/ez-enhertu